R&D Programs

SignalChem Plantech Inc. is a leading biotechnology subsidiary specializing in plant biosynthesis. We focus on the production of recombinant proteins, small molecules, and innovative applications that address critical health and agricultural challenges through advanced technologies and sustainable practices.

1. Recombinant Protein Production

We have successfully developed a diverse range of recombinant protein products, including:

  • New types of bio-stimulants (Harpin proteins)
  • Allergenic Proteins
  • Angiotensin-converting enzyme 2 (ACE2)

To meet the increasing market demands, we are actively seeking partners to expand our production facilities and capabilities.

2. Biostimulant Program

SignalChem Plantech is at the forefront of exploring and developing novel bio-stimulant ingredients. Our efforts include:

  • Tailored Formulations and innovative ingredients: Customized to enhance agricultural practices and Chinese herbal medicine.
  • Innovative Solutions: Addressing diverse needs across industries, driving sustainable and effective agricultural improvements.

3. SLC1021 Project

With five patents filed, the project has completed its initial R&D phase and is progressing towards commercialization across various applications such as:

  • Functional Foods
  • Nutraceuticals
  • Pharmaceuticals
  • Cosmetics
  • Animal Feed Additives (Antibiotic Alternatives)

Licensing:

  • Wound and Skin Cares (Aegis Biopharmaceuticals Inc): Immunmax™ | Home Page
    Aegis Biopharmaceuticals, a subsidiary of SignalChem Plantech, is advancing the development of Phyto-P, a patented wound care product derived from SLC1021.
  • Dietary and Livestock Applications (Comesci Phytotech):菜元宝官网
    Exclusive rights for the use of SLC1021 in human dietary products and animal feed in mainland China have been licensed to Comesci Plytotech, a subsidiary of SignalChem

4. Plant-Based Drug Discovery & Development

Our drug discovery initiatives focus on developing candidates to combat metabolic disorders such as:

  • Diabetes
  • Obesity

Through innovative drug targets and therapeutic interventions, we aim to transform the management, treatment, and prevention of these conditions.